AR and neoplasm: Pharmacologically targeting WEE1 (WEE1 inhibitor) combined with androgen receptor pathway inhibitor or glucocorticoid receptor modulators resensitized SOX2-positive PCa cells to NHRSI in vitro, and the combination of WEE1 inhibitor and androgen receptor pathway inhibitor substantially retarded tumor growth in vivo (Fig. 3B).